Recursion Pharmaceuticals, Inc.
RXRX
$4.53
-$0.108-2.33%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -202.49M | -178.91M | -95.84M | -97.54M | -91.37M |
| Total Depreciation and Amortization | 19.33M | 12.95M | 7.20M | 8.97M | 7.38M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 57.05M | 44.48M | 26.75M | 16.62M | 18.15M |
| Change in Net Operating Assets | -5.85M | 6.05M | 2.67M | -10.26M | -36.45M |
| Cash from Operations | -131.96M | -115.43M | -59.23M | -82.22M | -102.30M |
| Capital Expenditure | -1.83M | -1.30M | -4.56M | -1.18M | -6.65M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | 277.10M | -- | -- | -- |
| Divestitures | -4.44M | -- | -- | -- | -- |
| Other Investing Activities | -1.00M | -350.00K | 0.00 | -3.00M | -- |
| Cash from Investing | -7.27M | 275.46M | -4.56M | -4.18M | -6.65M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -2.05M | -2.10M | -2.29M | -26.00K | -26.00K |
| Issuance of Common Stock | 42.57M | 12.74M | 18.75M | 263.15M | 13.92M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 40.53M | 10.64M | 16.46M | 263.12M | 13.90M |
| Foreign Exchange rate Adjustments | 4.83M | -3.47M | 403.00K | -118.00K | -219.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -93.87M | 167.19M | -46.92M | 176.60M | -95.28M |